Header Logo

Connection

CLIONA ROONEY to Epstein-Barr Virus Nuclear Antigens

Back to Details
This is a "connection" page, showing publications CLIONA ROONEY has written about Epstein-Barr Virus Nuclear Antigens.
CLIONA ROONEY
Connection Strength
0.787
Epstein-Barr Virus Nuclear Antigens
  1. An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs. Blood. 2001 Feb 15; 97(4):835-43.
    View in: PubMed
    Score: 0.184
  2. Systemic inflammatory response syndrome after administration of unmodified T lymphocytes. Mol Ther. 2014 Jun; 22(6):1134-1138.
    View in: PubMed
    Score: 0.114
  3. EBNA3B-deficient EBV promotes B cell lymphomagenesis in humanized mice and is found in human tumors. J Clin Invest. 2012 Apr; 122(4):1487-502.
    View in: PubMed
    Score: 0.099
  4. Evidence for the presentation of major histocompatibility complex class I-restricted Epstein-Barr virus nuclear antigen 1 peptides to CD8+ T lymphocytes. J Exp Med. 2004 Feb 16; 199(4):459-70.
    View in: PubMed
    Score: 0.057
  5. Identification of a naturally processed HLA-DR-restricted T-helper epitope in Epstein-Barr virus nuclear antigen type 1. J Immunother. 2003 May-Jun; 26(3):212-21.
    View in: PubMed
    Score: 0.054
  6. Identification of HLA-DP3-restricted peptides from EBNA1 recognized by CD4(+) T cells. Cancer Res. 2002 Dec 15; 62(24):7195-9.
    View in: PubMed
    Score: 0.052
  7. Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies. Blood. 2003 Mar 01; 101(5):1905-12.
    View in: PubMed
    Score: 0.052
  8. Epstein-Barr Virus (EBV)-derived BARF1 encodes CD4- and CD8-restricted epitopes as targets for T-cell immunotherapy. Cytotherapy. 2019 02; 21(2):212-223.
    View in: PubMed
    Score: 0.039
  9. Cytotoxic T cells and immunotherapy. Pediatr Radiol. 1998 Jul; 28(7):489-91.
    View in: PubMed
    Score: 0.038
  10. Complementation of antigen-presenting cells to generate T lymphocytes with broad target specificity. J Immunother. 2014 May; 37(4):193-203.
    View in: PubMed
    Score: 0.029
  11. Host cell and EBNA-2 regulation of Epstein-Barr virus latent-cycle promoter activity in B lymphocytes. J Virol. 1992 Jan; 66(1):496-504.
    View in: PubMed
    Score: 0.024
  12. Influence of Burkitt's lymphoma and primary B cells on latent gene expression by the nonimmortalizing P3J-HR-1 strain of Epstein-Barr virus. J Virol. 1989 Apr; 63(4):1531-9.
    View in: PubMed
    Score: 0.020
  13. Antigenic and sequence variation in the C-terminal unique domain of the Epstein-Barr virus nuclear antigen EBNA-1. Virology. 1995 Apr 20; 208(2):521-30.
    View in: PubMed
    Score: 0.008
  14. New type B isolates of Epstein-Barr virus from Burkitt's lymphoma and from normal individuals in endemic areas. J Gen Virol. 1987 Nov; 68 ( Pt 11):2853-62.
    View in: PubMed
    Score: 0.005
  15. Selective lack of antibody to a component of EB nuclear antigen in patients with chronic active Epstein-Barr virus infection. J Infect Dis. 1987 Jul; 156(1):26-35.
    View in: PubMed
    Score: 0.004
  16. Epstein-Barr virus status and tumour cell phenotype in sporadic Burkitt's lymphoma. Int J Cancer. 1986 Mar 15; 37(3):367-73.
    View in: PubMed
    Score: 0.004
  17. Distinctions between endemic and sporadic forms of Epstein-Barr virus-positive Burkitt's lymphoma. Int J Cancer. 1985 Apr 15; 35(4):435-41.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.